54. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease?
55. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids.
56. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.
57. Zampelas A, Roche H, Knapper JM, et al. Differences in postprandial lipaemic response between Northern and Southern Europeans.
58. Perez-Jimenez F, Lopez-Miranda J, Mata P. Protective effect of dietary monounsaturated fat on arteriosclerosis: beyond cholesterol.
59. Dubnov G, Berry EM. Omega-6/omega-3 fatty acid ratio: the Israeli paradox.
60. Yam D, Eliraz A, Berry EM. Diet and disease – the Israeli paradox: possible dangers of a high omega-6 polyunsaturated fatty acid diet.
61. Renaud S, de Lorgeril M, Delaye J, et al. Cretan Mediterranean diet for prevention of coronary heart disease.
62. Covas MI, Nyyssonen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial.
63. Там же.
64. Is your olive oil fake? [Интернет]. Mercola.com. 2016 Dec 17 [открыто 4 июня 2018]. Доступно по адресу https://articles.mercola.com/sites/articles/archive/2016/12/17/fake-olive-oil.aspx.
1. Borkman M, Storlien LH, Pan DA, et al. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids.
2. Vessby B, Gustafsson IB, Tengblad S, et al. Desaturation and elongation of Fatty acids and insulin action.
3. de Lorgeril M, Salen P, Defaye P, et al. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?
4. Rise P, Ghezzi S, Priori I, et al. Differential modulation by simvastatin of the metabolic pathways in the n-9, n-6 and n-3 fatty acid series, in human monocytic and hepatocytic cell lines.
5. de Lorgeril M, Salen P, Guiraud A, et al. Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
6. Nozue T, Yamamoto S, Tohyama S, et al. Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
7. Harris JI, Hibbeln JR, Mackey RH, et al. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients.
8. Kurisu S, Ishibashi K, Kato Y, et al. Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease.
9. Nozue T, Yamamoto S, Tohyama S, et al. Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease.
10. Morris DH. Metabolism of alpha-linolenic acid.
11. Barcelo-Coblijn G, Murphy EJ. Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels.
12. Al MD, Badart-Smook A, von Houwelingen AC, et al. Fat intake of women during normal pregnancy: relationship with maternal and neonatal essential fatty acid status.
13. Carlson SE, Werkman SH, Peeples JM, et al. Long-chain fatty acids and early visual and cognitive development of preterm infants.
14. Hornstra G. Essential fatty acids in mothers and their neonates.
15. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women.
16. Docosahexaenoic acid (DHA). Monograph.
